1-O-alkyl-glycerols from Squid Berryteuthis magister Reduce Inflammation and Modify Fatty Acid and Plasmalogen Metabolism in Asthma Associated with Obesity
Marine Drugs · 2023
DOI: 10.3390/md21060351 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Drugs, 2023. Verfasst von Yulia Denisenko und 7 weiteren Autor:innen. Beteiligte Einrichtung: Vladivostok Branch of Far Eastern Scientific Center of Physiology and Pathology of Respiration, Institute of Medical Climatology and Rehabilitative T…. Hauptthemen laut MEDLINE: Fatty Acids, Asthma. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education of the Russian Federation, BIONIKA LLC, Tyumen, Russia.
Abstract (Originalsprache)
Asthma associated with obesity is considered the most severe phenotype and can be challenging to manage with standard medications. Marine-derived 1-O-alkyl-glycerols (AGs), as precursors for plasmalogen synthesis, have high biological activity, making them a promising substance for pharmacology. This study aimed to investigate the effect of AGs from squid Berryteuthis magister on lung function, fatty acid and plasmalogen levels, and cytokine and adipokine production in obese patients with asthma. The investigational trial included 19 patients with mild asthma associated with obesity who received 0.4 g of AGs daily for three months in addition to their standard treatment. The effects of AGs were evaluated at one and three months of treatment. The results of the study demonstrated that intake of AGs increased the FEV1 and FEV1/VC ratios, and significantly decreased the ACQ score in 17 of the 19 patients after three months of treatment. The intake of AGs increased concentration of plasmalogen and n–3 PUFA in plasma, and modified leptin/adiponectin production by adipose tissue. The supplementation of AGs decreased the plasma levels of inflammatory cytokines (TNF-α, IL-4, and IL-17a), and oxylipins (TXB2 and LTB4), suggesting an anti-inflammatory property of AGs. In conclusion, 1-O-alkyl-glycerols could be a promising dietary supplement for improving pulmonary function and reducing inflammation in obese asthma patients, and a natural source for plasmalogen synthesis. The study highlighted that the beneficial effects of AG consumption can be observed after one month of treatment, with gradual improvement after three months of supplementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vladivostok Branch of Far Eastern Scientific Center of Physiology and Pathology of Respiration, Institute of Medical Climatology and Rehabilitative Treatment, 690105 Vladivostok, Russia.
- A.V. Zhirmunsky National Scientific Center of Marine Biology (Far Eastern Branch), Russian Academy of Sciences, 17 Palchevskogo Str., 690041 Vladivostok, Russia.
Förderung
- Ministry of Science and Higher Education of the Russian Federation
- BIONIKA LLC, Tyumen, Russia
Zitieren
APA
Denisenko, Y., Novgorodtseva, T., Antonyuk, M., Yurenko, A., Gvozdenko, T., Kasyanov, S., Ermolenko, E., & Sultanov, R. (2023). 1-O-alkyl-glycerols from Squid Berryteuthis magister Reduce Inflammation and Modify Fatty Acid and Plasmalogen Metabolism in Asthma Associated with Obesity. Marine Drugs. https://doi.org/10.3390/md21060351
Vancouver
Denisenko Y, Novgorodtseva T, Antonyuk M, Yurenko A, Gvozdenko T, Kasyanov S, et al. 1-O-alkyl-glycerols from Squid Berryteuthis magister Reduce Inflammation and Modify Fatty Acid and Plasmalogen Metabolism in Asthma Associated with Obesity. Marine Drugs. 2023. doi:10.3390/md21060351
BibTeX
@article{Denisenko2023,
author = {Denisenko, Yulia and Novgorodtseva, Tatyana and Antonyuk, Marina and Yurenko, Alla and Gvozdenko, Tatyana and Kasyanov, Sergey and Ermolenko, Ekaterina and Sultanov, Ruslan},
title = {1-O-alkyl-glycerols from Squid Berryteuthis magister Reduce Inflammation and Modify Fatty Acid and Plasmalogen Metabolism in Asthma Associated with Obesity},
journal = {Marine Drugs},
year = {2023},
doi = {10.3390/md21060351}
}
EUVIMED